BR0311885A - Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente - Google Patents

Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente

Info

Publication number
BR0311885A
BR0311885A BR0311885-1A BR0311885A BR0311885A BR 0311885 A BR0311885 A BR 0311885A BR 0311885 A BR0311885 A BR 0311885A BR 0311885 A BR0311885 A BR 0311885A
Authority
BR
Brazil
Prior art keywords
treatment
prophylaxis
tissue
adenosine
patient
Prior art date
Application number
BR0311885-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Sherry A Leonard
Keith A Johnson
Original Assignee
Epigenesis Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Llc filed Critical Epigenesis Pharmaceuticals Llc
Publication of BR0311885A publication Critical patent/BR0311885A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
BR0311885-1A 2002-06-17 2003-06-17 Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente BR0311885A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38924202P 2002-06-17 2002-06-17
US47798703P 2003-06-11 2003-06-11
PCT/US2003/018945 WO2003105775A2 (en) 2002-06-17 2003-06-17 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof

Publications (1)

Publication Number Publication Date
BR0311885A true BR0311885A (pt) 2005-04-05

Family

ID=29740120

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0311885-1A BR0311885A (pt) 2002-06-17 2003-06-17 Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente
BR0311883-5A BR0311883A (pt) 2002-06-17 2003-06-17 Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do paciente

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0311883-5A BR0311883A (pt) 2002-06-17 2003-06-17 Recipiente selado, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento da doença pulmonar obstrutiva crÈnica, para a redução ou exaustão da adenosina em um tecido do paciente e para profilaxia ou tratamento de um distúrbio ou condição associada com nìveis altos de adenosina ou sensibilidade à adenosina em um tecido do paciente

Country Status (11)

Country Link
US (1) US20090087389A1 (https=)
EP (2) EP1553954A4 (https=)
JP (2) JP2005537296A (https=)
KR (2) KR101005819B1 (https=)
CN (2) CN1681520A (https=)
AU (2) AU2003276836B2 (https=)
BR (2) BR0311885A (https=)
CA (2) CA2491846A1 (https=)
IL (2) IL165378A0 (https=)
MX (2) MXPA04012720A (https=)
WO (2) WO2003105775A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
JP2008543806A (ja) * 2005-06-17 2008-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療のためのｍｒｐｉｖインヒビター
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
EP2010153A2 (en) * 2006-04-03 2009-01-07 Teva Pharmaceutical Industries Limited Drug microparticles
AU2008259768B2 (en) * 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
JP5711135B2 (ja) 2008-10-24 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド 胃腸疾患を治療するための方法
WO2010068754A2 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
AU2014239959A1 (en) * 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
WO2014172706A1 (en) * 2013-04-19 2014-10-23 University Of Houston System Cocrystalline dhea formulations
WO2025076250A1 (en) * 2023-10-04 2025-04-10 The Trustees Of Indiana University Slow-release compositions and methods for inflammatory airway obstruction

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943987A (en) * 1974-10-17 1976-03-16 Rossi Thomas J Reclosable air-tight containers with evacuation means
US4379842A (en) * 1980-02-13 1983-04-12 Hoffmann-La Roche Inc. Process for the manufacture of 1α-hydroxydehydroepiandrosterone
US4393066A (en) * 1981-06-05 1983-07-12 Garrett David M Method for treatment of herpetic lesions
US4499064A (en) * 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
CH673459A5 (https=) * 1987-05-15 1990-03-15 Eprova Ag
DE58902094D1 (de) * 1988-01-28 1992-10-01 Koeltringer Peter Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
FR2631828B1 (fr) * 1988-05-27 1994-05-20 Spiral Recherche Developpement Utilisation d'une substance folinique en tant qu'agent antiagregant plaquettaire
US4931441A (en) * 1988-11-09 1990-06-05 Luitpold Pharmaceuticals, Inc. Stabilized aqueous leucovorin calcium compositions
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
IT1229517B (it) * 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
NL8901432A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Bij koelkasttemperatuur stabiele waterige folinaatoplossing, alsmede werkwijze ter bereiding daarvan.
US4985443A (en) * 1989-08-04 1991-01-15 Montes Leopoldo F Method and composition for treating vitiligo
US5173488A (en) * 1989-08-21 1992-12-22 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
US5266312A (en) * 1992-01-07 1993-11-30 National Jewis Center For Immunology And Respiratory Medicine Method for treating a steroid resistant condition via administration of gamma interferon
ATE193447T1 (de) * 1992-02-24 2000-06-15 Univ East Carolina Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
US5686438A (en) * 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
SK286051B6 (sk) * 1993-01-19 2008-02-05 Endorecherche Inc. Použitie prekurzora pohlavného steroidu na prípravu liečiva na prevenciu alebo liečenie znížených alebo nevyrovnaných koncentrácií pohlavných steroidov
US5635496A (en) * 1993-03-09 1997-06-03 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5811418A (en) * 1993-03-09 1998-09-22 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
ATE283052T1 (de) * 1993-03-09 2004-12-15 Univ Utah Res Found Verwendung von dhea oder dessen derivate zur herstellung eines medikaments zur vorbeugung von progressiver gewebe-nekrose, reperfusionsschädigung, bakterieller translokation und vom atemnotsyndrom bei erwachsenen
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
EP0796112A4 (en) * 1994-11-30 1999-12-01 Amur Research Corp MEDICINAL DERIVATIVES OF PHOSPHOCHOLIN
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
US5767278A (en) * 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
EP1806131A3 (en) * 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
US5861391A (en) * 1997-01-29 1999-01-19 Research Development Foundation Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
AU763307B2 (en) * 1998-02-04 2003-07-17 Charlotte-Mecklenburg Hospital Authority Androsterone derivatives for inhibiting DNA binding of AP-1 and airway smooth muscle proliferation
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
PL200941B1 (pl) * 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
RU2220727C2 (ru) * 1999-03-18 2004-01-10 Дженелабс Текнолоджис, Инк. Композиция, содержащая дегидроэпиандростерон, и способы ее изготовления и применения
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof

Also Published As

Publication number Publication date
CN1658884A (zh) 2005-08-24
CA2489124A1 (en) 2004-12-02
MXPA04012728A (es) 2006-02-02
CN1681520A (zh) 2005-10-12
AU2003276836A1 (en) 2004-02-23
AU2003269889A1 (en) 2003-12-31
IL165378A0 (en) 2006-01-15
BR0311883A (pt) 2005-04-05
CN100540007C (zh) 2009-09-16
AU2003269889B2 (en) 2007-04-19
JP2005537296A (ja) 2005-12-08
WO2004012653A2 (en) 2004-02-12
EP1513509A4 (en) 2009-05-27
WO2004012653A3 (en) 2004-07-08
MXPA04012720A (es) 2007-03-23
KR20060011784A (ko) 2006-02-03
EP1553954A4 (en) 2009-12-23
EP1553954A2 (en) 2005-07-20
JP2005530820A (ja) 2005-10-13
KR101005819B1 (ko) 2011-01-05
KR20050037515A (ko) 2005-04-22
WO2003105775A2 (en) 2003-12-24
WO2003105775A3 (en) 2004-04-08
CA2491846A1 (en) 2003-12-24
IL165291A0 (en) 2005-12-18
AU2003276836B2 (en) 2007-05-10
US20090087389A1 (en) 2009-04-02
EP1513509A2 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
BR0311885A (pt) Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente
Lavorini et al. Dilemmas, confusion, and misconceptions related to small airways directed therapy
ES2266322T3 (es) Nuevo uso de budesonida y formoterol.
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
Madney et al. The influence of changing interfaces on aerosol delivery within high flow oxygen setting in adults: an in-vitro study
Buhl et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
Millar et al. Effect of oral N-acetylcysteine on mucus clearance
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
CN121623072A (zh) 用于治疗、改善或预防微生物感染的制造产品和方法
BR0309115A (pt) Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
Silverman Calcitonin
GB2430623A (en) Medicaments for treating chronic respiratory disease
TWI253930B (en) Novel combination of loteprednol and beta2 adrenoceptor agonists
MXPA06008240A (es) Metodos de tratamiento.
Berger et al. Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once-and twice-daily dosing in patients with asthma
Bousquet et al. Montelukast in guidelines and beyond
FitzGerald et al. Achieving asthma control in patients with moderate disease
Lanz et al. The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast
ES2248153T3 (es) Uso de oxido nitrico para el tratamiento de la construccion de las vias aereas.
Torres-Larrosa et al. Nasal leprosy: impact of multitherapy in the morphology and physiology of the nose
Desai et al. Perioperative management of patients with post Covid rhino-orbito-cerebral mucormycosis: Perspective observational study
Lipworth Three drugs in one inhaler for COPD: where are we going with triple therapy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 31/56, A61P 11/00

Ipc: A61K 31/56 (2011.01), A61P 11/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.